Jarmukhanov Zharkyn, Mukhanbetzhanov Nurislam, Kozhakhmetov Samat, Nurgaziyev Madiyar, Sailybayeva Aliya, Bekbossynova Makhabbat, Kushugulova Almagul
Laboratory of Microbiome, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan.
Heart Center, CF "University Medical Center", Astana, Kazakhstan.
Front Microbiol. 2024 Sep 26;15:1440241. doi: 10.3389/fmicb.2024.1440241. eCollection 2024.
This systematic review explores the relationship between the gut microbiota metabolite trimethylamine N-oxide (TMAO) and heart failure (HF), given the significant impact of TMAO on cardiovascular health. A systematic search and meta-analysis of peer-reviewed studies published from 2013 to 2024 were conducted, focusing on adult patients with heart failure and healthy controls. The review found that elevated levels of TMAO are associated with atherosclerosis, endothelial dysfunction, and increased cardiovascular disease risk, all of which can exacerbate heart failure. The analysis also highlights that high TMAO levels are linked to reduced left ventricular ejection fraction (LVEF) and glomerular filtration rate (GFR), further supporting TMAO's role as a biomarker in heart failure assessment. The findings suggest that interventions targeting gut microbiota to reduce TMAO could potentially benefit patients with heart failure, although further research is needed to evaluate the effectiveness of such approaches.
鉴于氧化三甲胺(TMAO)对心血管健康有重大影响,本系统评价探讨了肠道微生物群代谢产物TMAO与心力衰竭(HF)之间的关系。我们对2013年至2024年发表的同行评审研究进行了系统检索和荟萃分析,重点关注成年心力衰竭患者和健康对照。该评价发现,TMAO水平升高与动脉粥样硬化、内皮功能障碍及心血管疾病风险增加相关,所有这些都会加重心力衰竭。分析还强调,高TMAO水平与左心室射血分数(LVEF)降低和肾小球滤过率(GFR)降低有关,进一步支持了TMAO作为心力衰竭评估生物标志物的作用。研究结果表明,针对肠道微生物群以降低TMAO的干预措施可能会使心力衰竭患者受益,尽管需要进一步研究来评估这些方法的有效性。